psychiatryПСИХИАТРИЯPsychiatry (Moscow) (Psikhiatriya)1683-83192618-6667FSBSI “The Mental Health Research Centre”; LLC «Publisher «MIA»10.30629/2618-6667-2017-76-97-107psychiatry-300Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSСочетание нейродегенеративных и сосудистых механизмов в патогенезе деменций позднего возрастаThe combination of neurodegenerative and vascular mechanisms in the pathway of old age dementiaПономареваЕлена ВалерьевнаPonomarevaElena

кандидат медицинских наук, старший научный сотрудник

PhD, MD, candidate of medical sciences, senior researcher

elena-pon@hotmail.comТелешоваЕвгения СергеевнаTeleshovaEvgenia

кандидат медицинских наук, врач-психиатр, старший научный сотрудник

PhD, MD, candidate of medical sciences, psychiatrist, senior researcher

eteleshova@mail.ruСюняковТимур СергеевичSyunyakovTimur

кандидат медицинских наук, старший научный сотрудник,  медицинский советник

PhD, MD, candidate of medical sciences, senior researcher, medical advisor

sjunja@bk.ruФГБНУ «Научный центр психического здоровья», МоскваРоссияFSBSI «Mental Health Research Centre», MoscowRussian FederationНПЦ психоневрологии им. З.П. Соловьева, Москва; ФГБНУ «НИИ фармакологии им. В.В. Закусова», МоскваРоссияResearch-Practical Psychoneurological Center, Moscow; FSBI «Zakusov Institute of Pharmacology», MoscowRussian FederationФГБНУ «НИИ фармакологии им. В.В. Закусова», Москва; ООО Pfizer, МоскваРоссияFSBI «Zakusov Institute of Pharmacology», Moscow; Pfizer LLC, MoscowRussian Federation20172812201707697107Copyright © Пономарева Е.В., Телешова Е.С., Сюняков Т.С., 20172017Пономарева Е.В., Телешова Е.С., Сюняков Т.С.Ponomareva E., Teleshova E., Syunyakov T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.journalpsychiatry.com/jour/article/view/300

Цель работы: провести анализ данных литературы о возможности сочетания нейродегенеративных и сосудистых механизмов в развитии деменций позднего возраста. Материал и метод: в статье проведен анализ научных публикаций об участии нейродегенеративного и сосудистого механизмов в развитии деменции позднего возраста. Представлены особенности их патогенеза и взгляды на возможную взаимосвязь этих процессов. Проанализированы современные подходы к медикаментозной коррекции этих расстройств, описан спектр биохимической активности и механизм действия основных средств терапии деменции. Вывод: анализ данных литературы свидетельствует об общности факторов риска, перекрестном патогенезе и возможном аддитивном и синергическом взаимодействии атрофического и сосудистого процесса головного мозга при развитии деменции.

The aim of the study is to analyze literature data about the possibility of the combination of neurodegenerative and vascular mechanisms in the development of old age dementia. Material and method: this review describes the analysis of the literature on the participation of neurodegenerative and vascular mechanisms in the development of dementia. The literature review concerned the assessment of its pathogenic mechanisms and the possible relationship between these processes. It was analyzed the modern approaches to pharmacological correction of these disorders, including the range of biochemical activity and mechanisms of action of the main directions of therapy of dementia. Conclusion: the analysis of literary data demonstrates the commonality of risk factors, the presence of intersecting pathogenetic processes and the possibility of the additive and synergistic interaction of vascular and atrophic brain processes.

поздний возрастдеменциикогнитивные расстройствапатогенезлечениеold agedementiacognitive disorderspathwaytreatmentReferencesAbbott A. Dementia: a problem for our age. Nature. 2011;475(7355):2–4. doi.org/10.1038/475s2aAbbott A. Dementia: a problem for our age. Nature. 2011;475(7355):2–4. doi.org/10.1038/475s2aGustavsson A., Svensson M., Jacobi F., Allgulander C., Alonso J., Beghi E., Dodel R., Ekman M., Faravelli C., Fratiglioni L., Gannon B., Hilton Jones D., Jennum P., Jordanova A., Jönsson L., Karampampa K., Knapp M., Kobelt G., Kurth T., Lieb R., Linde M., Ljungcrantz C., Maercker A., Melin B., Moscarelli M., Musayev A., Norwood F., Preisig M., Pugliatti M., Rehm J., Carulla L.-S., Schlehofer B., Simon R., Steinhausen H.-C., Stovner L.J., Vallat J.-M., Bergh P., Os J., Vos P., Xu W., Wittchen H.-U., Jönsson B., Olesen J. Cost of disorders of the brain in Europe. Eur. Neuropsychopharmacol. 2011; 21(10): 718– 779. https://doi.org/10.1016/j.euroneuro.2012.01.001Gustavsson A., Svensson M., Jacobi F., Allgulander C., Alonso J., Beghi E., Dodel R., Ekman M., Faravelli C., Fratiglioni L., Gannon B., Hilton Jones D., Jennum P., Jordanova A., Jönsson L., Karampampa K., Knapp M., Kobelt G., Kurth T., Lieb R., Linde M., Ljungcrantz C., Maercker A., Melin B., Moscarelli M., Musayev A., Norwood F., Preisig M., Pugliatti M., Rehm J., Carulla L.-S., Schlehofer B., Simon R., Steinhausen H.-C., Stovner L.J., Vallat J.-M., Bergh P., Os J., Vos P., Xu W., Wittchen H.-U., Jönsson B., Olesen J. Cost of disorders of the brain in Europe. Eur. Neuropsy- chopharmacol. 2011; 21(10): 718–779. https://doi.org/10.1016/j. euroneuro.2012.01.001Olesen J., Gustavsson A., Svensson M., Wittchen H.-U., Jönsson B. The economic cost of brain disorders in Europe. Eur. J. Neurol. 2012;19(1):155–162. doi.org/10.1111/j.1468- 1331.2011.03590.xOlesen J., Gustavsson A., Svensson M., Wittchen H.-U., Jönsson B. The economic cost of brain disorders in Europe. Eur. J. Neurol. 2012;19(1):155–162. doi.org/10.1111/j.1468-1331.2011.03590.xJessen F. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers. Dement. 2013;9(4):824. doi: http://dx.doi.org/10.1016/j.jalz.2013.04.451Jessen F. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers. Dement. 2013; 9(4): 824. doi: http://dx.doi.org/10.1016/j.jalz.2013.04.451Гаврилова С.И., Вольпина О.М., Колыхалов И.В., Федорова Я.Б., Селезнева Н.Д., Пономарева Е.В., Короев Д.О., Камынина А.В. Терапевтический мониторинг и прогноз эффективности нейротрофической терапии у пациентов с синдромом мягкого когнитивного снижения амнестического типа. Журнал неврологии и психиатрии им. C.C. Корсакова. 2017;8:27–38.Gavrilova S.I., Vol'pina O.M., Kolykhalov I.V., Fedorova Ya.B., Selezneva N.D., Ponomareva E.V., Koroev D.O., Kamynina A.V. Terapevticheskii monitoring i prognoz effektivnosti neirotroficheskoi terapii u patsientov s sindromom myagkogo kognitivnogo snizheniya amnesticheskogo tipa. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;8:27–38. (In Russ.).Гаврилова С.И. Подходы к превентивной терапии болезни Альцгеймера: проблемы и возможности. Психиатрия. 2014;1:5–12.Gavrilova S.I. Approaches to preventive treatment of Alzheimer’s disease: problems and possibilities. Psychhiatry. 2014;1:5-12. (In Russ.).Гаврилова С.И., Колыхалов И.В., Фёдорова Я.Б., Калын Я.Б., Селезнёва Н.Д., Самородов А.В., Мясоедов С.Н., Бокша И.С. Прогноз прогрессирования когнитивного дефицита у пожилых пациентов с синдромом мягкого когнитивного снижения при длительном лечении (3-летнее наблюдение). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;3(1):45–53.Gavrilova S.I., Kolykhalov I.V., Fedorova Ya.B., Kalyn Ya.B., Selezneva N.D., Samorodov A.V., Myasoedov S.N., Boksha I.S. Prognoz progressirovaniya kognitivnogo defitsta u pozhilykh patsientov s sindromom myagkogo kognitivnogo snizheniya pri dlitel'nom lechenii (3-letnee nablyudenie). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;3(1):45–53. (In Russ.).Молочкина Е.М., Фаткуллина Л.Д., Подчуфарова Д.Е., Голощапов А.Н., Гаврилова С.И., Федорова Я.Б., Клюшник Т.П., Бурлакова Е.Б. Особенности структурно-функционального статуса мембран эритроцитов при синдроме мягкого когнитивного снижения. Психиатрия. 2014;1:21–26.Molochkina E. M., Fatkullina L. D., Podchufarova D. E., Goloshchapov A.N., Gavrilova S.I., Fedorova Ya.B., Klyushnik T.P., Burlakova E.B. Features of structural and functional status of erythrocyte membranes in the syndrome of mild cognitive impairment. Psychiatry. 2014;1:21–26. (In Russ.).Edmonds E.C., Delano-Wood L., Galasko D.R., Salmon D.P., Bondi M.W. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J. Int. Neuropsychol. Soc. NIH Public Access. 2014;20(8):836–847. https://doi.org/10.1017/s135561771400068xEdmonds E.C., Delano-Wood L., Galasko D.R., Salmon D.P., Bondi M.W. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J. Int. Neuropsychol. Soc. NIH Public Access 2014;20(8):836–847. https://doi.org/10.1017/ s135561771400068xPlassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., Burke J.R., Hurd M.D., Potter G.G., Rodgers W.L., Steffens D.C., Willis R.J., Wallace R.B. Prevalence of dementia in the United States: the aging, demographics, and memory study; Neuroepidemiology. 2007;29(1–2):125– 132. https://doi.org/10.1159/000109998Plassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., Burke J.R., Hurd M.D., Potter G.G., Rodgers W.L., Steffens D.C., Willis R.J.,. Wallace R.B. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1–2):125–132. https://doi.org/10.1159/000109998Viswanathan A., Rocca W.A., Tzourio C. Vascular risk factors and dementia: How to move forward? Neurology. 2009;72(4):368–374. http://dx. doi. org/10.1212/ 01. wnl. 0000341271.90478.8eViswanathan A., Rocca W.A., Tzourio C. Vascular risk factors and dementia: How to move forward? Neurology. 2009;72(4):368–374. http://dx.doi.org/10.1212/01.wnl.0000341271.90478.8eKalaria R.N., Ballard C. Overlap between pathology of Alzheimer’s disease and vascular dementia. Alzheimer disease and Associated disorders. 1999;13(3):115–123. Doi: 10.1097/00002093-199912003-00017Kalaria R.N., Ballard C. Overlap between pathology of Alzheimer’s disease and vascular dementia. Alzheimer disease and Associated disorders. 1999;13(3):115–123. doi: 10.1097/00002093-199912003-00017Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA. 2004;292(23):2901–2908. doi:10.1001/jama.292.23.2901Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA. 2004;292(23):2901– 2908. doi:10.1001/jama.292.23.2901Руководство по гериатрической психиатрии. Под ред. С.И. Гавриловой. М: Пульс, 2011:113–129. ISBN 978-5-93486- 065-4Rukovodstvo po geriatricheskoi psikhiatrii. Pod red. S.I. Gavrilovoi. M.: Pul's. 2011:113–129. ISBN 978-5-93486-065-4. (In Russ.).Гаврилова С.И., Калын Я.Б. Социальные факторы и психические расстройства в пожилом и старческом возрасте. В кн.: Руководство по социальной психиатрии. Под ред. Т.Б. Дмитриевой. М.: «Медицина»; 2001:136–161.Gavrilova S.I., Kalyn Ya.B. Sotsial'nye faktory i psikhicheskie rasstroistva v pozhilom i starcheskom vozraste. V kn.: Rukovodstvo po sotsial'noi psikhiatrii. Pod red. T.B. Dmitrievoi. M. «Meditsina»; 2001:136-161. (In Russ).Михайлова Н.М. Диагностика и терапия смешанной (аль- цгеймеровско-сосудистой) деменции. Современная терапия в психиатрии и неврологии. 2012;3:18–26.Mikhailova N.M. Diagnostika i terapiya smeshannoi (al'tsgeimerovsko-sosudistoi) dementsii. Sovremennaya terapiya v psikhiatrii i nevrologii. 2012;3:18–26. (In Russ.).Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197–2204. doi: http://dx.doi.org/10.1212/01.wnl. 0000271090.28148.24Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007; 69: 2197–2204. doi: http://dx.doi.org/10.1212/01.wnl.0000271090.28148.24Левин О.С. Диагностика и лечение деменции в клинической практике. М.: «Медпресс-информ»; 2010:255.Levin O.S. Diagnostika i lechenie dementsii v klinicheskoi praktike. M.: «Medpress-inform»; 2010:255. (In Russ).Михайлова Н.М., Рощина И.Ф. Смешанная альцгеймеровско-сосудистая деменция. Ч. 1. Психиатрия. 2012; 53–55(1–3):24–37.Mikhailova N.M., Roshchina I.F. Mixed Dementia. Part 1. The Clinical and Neuropsychological Aspects. Psychiatry. 2012;53– 55(1–3):24–37. (In Russ.).Михайлова Н.М., Божко О.В. Смешанная альцгеймеровско-сосудистая деменция. Ч. 2. Психиатрия. 2012; 53– 55(1–3):38–58.Mikhailova N.M., Bozhko O.V. Mixed Dementia. Part 2. Psychiatry. 2012;53–55(1– 3):38–58. (In Russ.).Jellinger K.A., Attems J. Incidence of cerebrovascular lesions in Alzheimer’s disease: a postmortem study. Acta Neuropathol. 2003;105(1):14–17.Jellinger K.A., Attems J. Incidence of cerebrovascular lesions in Alzheimer’s disease: a postmortem study. Acta Neuropathol. 2003;105(1):14–17.Masters C.L., Bateman R., Blennow K., Rowe C.C., Sperling R.A., Cummings J.L. Alzheimer’s disease Nat. Publ. Gr. 2015;1:15056. https://doi.org/10.1038/nrdp.2015.56Masters C.L., Bateman R., Blennow K., Rowe C.C., Sperling R.A., Cummings J.L. Alzheimer’s disease Nat. Publ. Gr. 2015;1:15056. https://doi.org/10.1038/nrdp.2015.56Silvestre J.-S., Smadja D. M., Levy B. I. Postischemic revascularization: From cellular and molecular mechanisms to clinical applications. Physiol. Rev. 2013;93(4):1743–1802. https://doi.org/10.1152/physrev.00006.2013Silvestre J.-S., Smadja D.M., Levy B.I. Postischemicrevascularization: rom cellular and molecular mechanisms to clinical applications. Physiol. Rev. 2013;93(4):1743–1802. https://doi.org/10.1152/physrev.00006.2013Zaleska M.M., Mercado M.L.T., Chavez J., Feuerstein G.Z., Pangalos M.N., Wood A. The development of stroke therapeutics: Promising mechanisms and translational challenges. Neuropharmacology. Elsevier Ltd, 2009;56(2):329–341. https://doi.org/10.1016/j.neuropharm.2008.10.006Zaleska M.M., Mercado M.L.T., Chavez J., Feuerstein G.Z., Pangalos M.N., Wood A. The development of stroke therapeutics: Promising mechanisms and translational challenges. Neuropharmacology. Elsevier Ltd, 2009;56(2):329–341. https://doi.org/10.1016/j.neuropharm.2008.10.006Gorelick P.B. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004;35(11):2620–2622. https:// doi.org/10.1161/01.str.0000143318.70292.47Gorelick P.B. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004;35(11):2620–2622. https://doi.org/10.1161/01.str.0000143318.70292.47Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience. 2011;12:723–738. doi:10.1038/nrn3114Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience. 2011;12:723–738. doi:10.1038/nrn3114Heppner F.L., Ransohoff R.M., Becher B. Immune attack: the role of inflammation in Alzheimer's disease. Nature Neuroscience. 2015;16(6):358–372. https://doi.org/10.1038/ nrn3880Heppner F.L., Ransohoff R.M., Becher B. Immune attack: the role of inflammation in Alzheimer's disease. Nature Neuroscience. 2015;16(6):358–372. https://doi.org/10.1038/nrn3880Mandrekar-Colucci S., Landreth G. E. Microglia and inflammation in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets. NIH Public Access. 2010;9(2):156–167. https://doi.org/10.2174/187152710791012071Mandrekar-Colucci S. , Landreth G. E. Microglia and inflammation in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets. NIH Public Access. 2010;9(2):156–167. https://doi.org/10.2174/187152710791012071Attems J., Jellinger K.A. The overlap between vascular disease and Alzheimer’s disease — lessons from pathology. BMC Medicine. 2014;12(1). https://doi.org/10.1186/s12916-014- 0206-2Attems J., Jellinger K.A. The overlap between vascular disease and Alzheimer’s disease — lessons from pathology. BMC Medicine. 2014;12(1). https://doi.org/10.1186/s12916-014-0206-2Olichney J.M. et al. Types of cerebrovascular lesions associ- ated with severe cerebral amyloid angiopathy in Alzheimer’s disease. Ann. N. Y. Acad. Sci. 1997;826(127):493–497. https://doi.org/10.1186/s12916-014-0206-2Olichney J.M. et al. Types of cerebrovascular lesions associated with severe cerebral amyloid angiopathy in Alzheimer’s disease. Ann. N. Y. Acad. Sci. 1997;826(127):493–497. https://doi.org/10.1186/s12916-014-0206-2Xu M., Zhang H. Death and survival of neuronal and astro- cytic cells in ischemic brain injury: a role of autophagy. Acta Pharmacol. Sin. 2011;32:1089–1099. https://doi.org/10.1038/aps.2011.50Xu M., Zhang H. Death and survival of neuronal and astrocytic cells in ischemic brain injury: a role of autophagy. Acta Pharmacol. Sin. 2011;32:1089–1099. https://doi.org/10.1038/aps.2011.50Cai Z., Xiao M. Oligodendrocytes and Alzheimer's disease. Int. J. Neurosci. 2016;126(2): 97–104. doi: 10.3109/00207454.2015.1025778Cai Z., Xiao M. Oligodendrocytes and Alzheimer's disease. Int. J. Neurosci. 2016;126(2):97–104. doi: 10.3109/00207454.2015.1025778Esposito Z., Belli L., Toniolo S., Sancesario G., Bianconi C., Martorana A. Amyloid β, glutamate, excitotoxicity in Alzheimer’s disease: Are we on the right track? CNS Neurosci. Ther. 2013;19(8):549–555. https://doi.org/10.1111/cns.12095Esposito Z., Belli L., Toniolo S., Sancesario G., Bianconi C., Martorana A. Amyloid β, glutamate, excitotoxicity in Alzheimer’s disease: Are we on the right track? CNS Neurosci. Ther. 2013;19(8):549–555. https://doi.org/10.1111/cns.12095Sorbera L.A., Bozzo J., Serradell N. Alzheimer’s disease one century later: The search for effective therapeutic targets continues. Drugs Future. 2007;32(7):625. https://doi.org/10.1358/dof.2007.032.07.1116862Sorbera L.A., Bozzo J., Serradell N. Alzheimer’s disease one century later: The search for effective therapeutic targets continues. Drugs Future. 2007;32(7):625. https://doi.org/10.1358/dof.2007.032.07.1116862Wang J., Zhang H.-Y., Tang X.-C. Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacol. Sin. 2009;30(30):879–888. https://doi.org/10.1038/aps.2009.82Wang J., Zhang H.-Y., Tang X.-C. Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacol. Sin. 2009;30(30):879–888. https://doi.org/10.1038/aps.2009.82Беккер P.А., Быков Ю.В. Мемантин: возможности и пер- спективы применения в психиатрии (обзор современных данных). Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2016;4:42–51.Bekker P.A., Bykov Yu.V. Memantin: vozmozhnosti i perspektivy primeneniya v psikhiatrii (obzor sovremennykh dannykh). Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. 2016;4:42–51. (In Russ.).Asai S., Zhao H., Yamashita A., Jike T., Kunimatsu T., Nagata T., Kohno T., Ishikawa K. Nicergoline enhances glutamate reuptake and protects against brain damage in rat global brain ischemia. Eur. J. Pharmacol. 1999;383(3):267–274. https://doi.org/10.1016/s0014-2999(99)00623-8Asai S., Zhao H., Yamashita A., Jike T., Kunimatsu T., Nagata T., Kohno T., Ishikawa K. Nicergoline enhances glutamate re-uptake and protects against brain damage in rat global brain ischemia. Eur. J. Pharmacol. 1999;383(3):267–274. https://doi.org/10.1016/s0014-2999(99)00623-8Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Chandrasekhar Rao Venkata Damaraju. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomized trial. Lancet. 2002;(359):1283–1290. https://doi.org/10.1016/s0140-6736(02)08267-3Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Chandrasekhar Rao Venkata Damaraju. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomized trial. Lancet. 2002;(359):1283–1290. https://doi.org/10.1016/s0140-6736(02)08267-3Kumar V., Anand R., Messina J., Hartman R., Veach J. An efficacy and safety analysis of Exelon in Alzheimer’s disease patients with concurrent vascular risk factors. Eur. J. Neurol. 2000;(7):159–169. https://doi.org/10.1046/j.1468-1331.2000.00046.xKumar V., Anand R., Messina J., Hartman R., Veach J. An efficacy and safety analysis of Exelon in Alzheimer’s disease patients with concurrent vascular risk factors. Eur. J. Neurol. 2000;(7):159–169. https://doi.org/10.1046/j.1468-1331.2000.00046.xOrgogozo J.M., Rigaud A.S., Stoffler A. et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834–1839. https://doi.org/10.1161/01.str.0000020094.08790.49Orgogozo J.M., Rigaud A.S., Stoffler A. et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834–1839. https://doi.org/10.1161/01. str.0000020094.08790.49Гаврилова С.И., Колыхалов И.В., Селезнева Н.Д., Жариков Г.А. и др. Двойное слепое плацебо-контролируемое исследование влияния церебролизина на эффективность и переносимость последующей холинергической терапии у больных с болезнью Альцгеймера. Социальная и клиническая психиатрия. 2000;2:41–46.Gavrilova S.I., Kolykhalov I.V., Selezneva N.D., Zharikov G.A. i dr. Dvoinoe slepoe platsebo-kontroliruemoe issledovanie vliyaniya tserebrolizina na effektivnost' i perenosimost'posleduyushchei kholinergicheskoi terapii u bol'nykh s bolezn'yu Al'tsgeimera. Sotsial'naia i klinich. psikhiatria. 2000;2:41–46. (In Russ.).Герасимов Н.П. Двойное слепое плацебо-контролируе- мое исследование эффективности церебролизина при болезни Альцгеймера. Социальная и клиническая психиатрия. 2000;2:35–40.Gerasimov N.P. Dvoinoe slepoe platsebo-kontroliruemoe issledovanie effektivnosti tserebrolizina pri bolezni Al'tsgeimera. Sotsial'naya i klinicheskaya psikhiatriya. 2000;2:35–40. (In Russ.).Alvarez X.A., Cacabelos R., Sampedro C., Couceiro V., Aleixandre M., Vargas M., Linares C., Granizo E., García-Fantini M., Baurecht W., Doppler E., Moessler H. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr. Alzheimer. Res. 2011;8(5):583–591. https://doi.org/10.2174/156720511796391863Alvarez X.A., Cacabelos R., Sampedro C., Couceiro V., Aleixandre M., Vargas M., Linares C., Granizo E., García-Fantini M., Baurecht W., Doppler E., Moessler H. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr. Alzheimer. Res. 2011;8(5):583– 591. https://doi.org/10.2174/156720511796391863Gauthier S., Proano J.V., Jia J., Froelich L., Vester J.C., Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Alzheimer’s and Dementia. 2014;10(4):859. https://doi.org/10.1016/j.jalz.2014.05.1709Gauthier S., Proano J.V., Jia J., Froelich L., Vester J.C., Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Alzheimer’s and Dementia. 2014;10(4):859. https://doi.org/10.1016/j.jalz.2014.05.1709Nishida A., Iwata H., Kudo Y., Kobayashi T., Matsuoka Y., Kanai Y., Endou H. Nicergoline enhances glutamate uptake via glutamate transporters in rat cortical synaptosomes. Biol. Pharm. Bull. 2004;27(6):817–820. https://doi.org/10.1248/bpb.27.817Nishida A., Iwata H., Kudo Y., Kobayashi T., Matsuoka Y., Kanai Y., Endou H. Nicergoline enhances glutamate uptake via glutamate transporters in rat cortical synaptosomes. Biol. Pharm. Bull. 2004;27(6):817–820. https://doi.org/10.1248/bpb.27.817Battaglia A., Bruni G., Ardia A., Sacchetti G. Nicergoline in mild to moderate dementia: a multicenter, double-blind, placebo-controlled study. J. Am. Geriatr. Soc. 1989; 37(4):295– 302. doi: 10.1111/j.1532-5415.1989.tb05494.xBattaglia A., Bruni G., Ardia A., Sacchetti G. Nicergoline in mild to moderate dementia: a multicenter, double-blind, placebo-controlled study. J. Am. Geriatr. Soc. 1989;37(4):295–302. doi: 10.1111/j.15325415.1989.tb05494.xNappi G., Bono G., Merlo P., Borromei A., Caltagirone C., Lomeo C., Martucci N., Fabbrini G., Annoni K., Battaglia A. Long-term nicergoline treatment of mild to moderate senile dementia: results of a multi-centre, double-blind, placebocontrolled study. Clin. Drug Invest. 1997;13(6):308–316. doi: 10.2165/00044011-199713060-00003Nappi G., Bono G., Merlo P., Borromei A., Caltagirone C., Lomeo C., Martucci N., Fabbrini G., Annoni K., Battaglia A. Long-term nicergoline treatment of mild to moderate senile dementia: results of a multi-centre, double-blind, placebocontrolled study. Clin. Drug Invest. 1997;13(6):308–316. doi: 10.2165/00044011-199713060-00003Радзивил Г.Г., Герасимов Н.П., Селезнева Н.Д., Красноперова М.Г. Состояние центральной гемодинамики у больных с деменцией альцгеймеровского типа в процессе терапии ницерголином // Болезнь Альцгеймера и старение: от нейробиологии к терапии. Москва. 1999;112–114.Radzivil G.G., Gerasimov N.P., Selezneva N.D., Krasnoperova M.G. Sostoyanie tsentral'noi gemodinamiki u bol'nykh s dementsiei al'tsgeimerovskogo tipa v protsesse terapii nitsergolinom. V kn. Bolezn' Al'tsgeimera i starenie: ot neirobiologii k terapii. Moskva. 1999;112–114. (In Russ.).Пономарева Е.В. Применение ницерголина (Сермиона) в комплексной терапии деменций позднего возраста в амбулаторной практике. Психиатрия. 2017;73(1):49–59.Ponomareva E.V. The use of Sermion in the complex therapy of outpatients with old age dementia. Psychiatry. 2017;73(1):49–59. (In Russ.).Winblad B., Carfagna N., Bonura L., Rossini B.M., Wong E.H.F., Battaglia A. Nicergoline in Dementia. CNS Drugs. Springer International Publishing. 2000;14(4):267–287. https://doi.org/10.2165/00023210-200014040-00003Winblad B., Carfagna N., Bonura L., Rossini B.M., Wong E.H.F., Battaglia A. Nicergoline in Dementia. CNS Drugs. Springer International Publishing. 2000;14(4):267–287. https://doi.org/10.2165/00023210-200014040-00003Fioravanti M., Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database of Systematic Reviews / ed. Fioravanti M. Chichester, UK: John Wiley & Sons, Ltd. 2001;4:CD003159. https://doi.org/10.1002/14651858.cd003159Fioravanti M., Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database of Systematic Reviews / ed. Fioravanti M. Chichester, UK: John Wiley & Sons, Ltd. 2001;4:CD003159. https://doi.org/10.1002/14651858.cd003159Matsuoka Y., Fukushima T., Iwata H., Matsumoto M., Shibutani Y., Kwashima K., Kudo Y., Ishida R. Inhibitory action of nicergoline and its metabolites on acetylcholinesterase activity in rats and mouse brain. Adv. Behav. Biol. 1990;38:415– 419. https://doi.org/10.1007/978-1-4684-5847-3_84Matsuoka Y., Fukushima T., Iwata H., Matsumoto M., Shibutani Y., Kwashima K., Kudo Y., Ishida R. Inhibitory action of nicergoline and its metabolites on acetylcholinesterase activity in rats and mouse brain. Adv. Behav. Biol. 1990;38:415–419. https://doi.org/10.1007/978-1-4684-5847-3_84Пономарева Е.В. Применение ницерголина в геронтологи- ческой практике. Психиатрия. 2016;3(71):106–120.Ponomareva E.V. The use of nicergoline in gerontological practice. Psychiatry. 2016;3(71):106–120. (In Russ.).Aguero-Torres H., Kivipelto M., von Strauss E. Rethinking the dementia diagnoses in a population-based study: what is Alzheimer’s disease and what is vascular dementia? A study from the Kungsholmen Project. Dement. Geriatr. Cogn. Disord. 2006;22(3):244–249. doi: 10.1159/000094973Aguero-Torres H., Kivipelto M., von Strauss E. Rethinking the dementia diagnoses in a population-based study: what is Alzheimer’s disease and what is vascular dementia? A study from the Kungsholmen Project. Dement. Geriatr. Cogn. Disord. 2006;22(3):244–249. doi: 10.1159/000094973Лобзин В.Ю. Комплексная ранняя диагностика нарушений когнитивных функций. Журн. неврологии и психиатрии им. С.С. Корсакова. 2015;115(11):72–79.Lobzin V.Yu. Kompleksnaya rannyaya diagnostika narushenii kognitivnykh funktsii. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(11):72–79. (In Russ.).Girouard H., Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J. Appl. Physiol. 2006;100 (1):328–335. doi: 10.1152/japplphysiol.00966.2005Girouard H., Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J. Appl. Physiol. 2006;100(1):328–335. doi: 10.1152/japplphysiol.00966.2005Roman G.C., Kalaria R.N. Vascular determinants of cholinergic deficits in Alzheimer's disease and vascular dementia. Neurobiol. Aging. 2006;27(12):1769–1785. doi: http://dx.doi.org/10.1016/j.neurobiolaging.2005.10.004Roman G.C., Kalaria R.N. Vascular determinants of cholinergic deficits in Alzheimer's disease and vascular dementia. Neurobiol. Aging. 2006;27(12):1769–1785. doi: http://dx.doi.org/10.1016/j.neurobiolaging.2005.10.004Santos C.Y., Snyder P.J., Wu W.-Ch., Zhang M., Echeverria A., Alber J. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement. (Amst). 2017;7:69–87. Published online 2017 Feb 9. doi: 10.1016/j. dadm.2017.01.005Santos C.Y., Snyder P. J., Wu W.-Ch., Zhang M., Echeverria A., Alber J. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement. (Amst). 2017;7:69–87. Published online 2017 Feb 9. doi: 10.1016/j.dadm.2017.01.005Ji F., Pasternak O., Liu S., Loke Y.M., Choo B.L., Hilal S., Xu X., Ikram M.K., Venketasubramanian N., Chen C.L.-H., Zhou J. Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer’s disease with and without cerebrovascular disease. Alzheimers Res. Ther. 2017;9:63. Published online 2017 Aug 17. doi: 10.1186/s13195-017-0292-4Ji F., Pasternak O., Liu S., Loke Y.M., Choo B.L., Hilal S., Xu X., Ikram M.K., Venketasubramanian N., Chen C.L.-H., Zhou J. Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer’s disease with and without cerebrovascular disease. Alzheimers Res. Ther. 2017;9:63. Published online 2017 Aug 17. doi: 10.1186/ s13195-017-0292-4Raz L., Knoefel J., Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J. Cereb. Blood Flow Metab. 2016Jan;36(1):172–186. doi: 10.1038/ jcbfm.2015.164.Raz L., Knoefel J., Bhaskar K. The neuropathology and cerebro- vascular mechanisms of dementia. J. Cereb. Blood Flow Metab. 2016Jan;36(1):172–186. doi: 10.1038/jcbfm.2015.164.

The authors declare that there are no conflicts of interest present.